AMY-101 (TFA)

CAT:
804-HY-P1717A-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
AMY-101 (TFA) - image 1

AMY-101 (TFA)

  • Description :

    AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs) . AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].
  • Product Name Alternative :

    Cp40 (TFA)
  • UNSPSC :

    12352209
  • Target :

    Complement System; SARS-CoV
  • Type :

    Peptides
  • Related Pathways :

    Anti-infection; Immunology/Inflammation
  • Applications :

    COVID-19-anti-virus
  • Field of Research :

    Inflammation/Immunology
  • Assay Protocol :

    https://www.medchemexpress.com/amy-101-tfa.html
  • Purity :

    99.92
  • Solubility :

    DMSO : ≥ 50 mg/mL|H2O : ≥ 50 mg/mL
  • Smiles :

    OC(C(F)(F)F)=O.CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@H]([C@@H](C)CC)NC([C@H](N)CC4=CC=C(C=C4)O)=O)=O)C(N(C)[C@H](C(N)=O)[C@@H](C)CC)=O)=O)CCCNC(N)=N)=O)CC5=CN=CN5)=O)C)=O)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1.[x]
  • Molecular Formula :

    C83H117N23O18S2.xC2HF3O2
  • Molecular Weight :

    1789.09 (free base)
  • References & Citations :

    [1]Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.|[2]Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.|[3]Yanyan Liu, et al. Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A Secretion. Front Immunol. 2018 Oct 22;9:2385.
  • Shipping Conditions :

    Blue Ice
  • Storage Conditions :

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
  • Scientific Category :

    Peptides
  • Clinical Information :

    Phase 2
  • Citation 01 :

    BioRxiv. 2025 May 23.|Cell. 2025 May 29;188 (11) :3013-3029.e19.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Sci Total Environ. 2024 May 10:924:171681.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Virulence. 2025 Dec;16 (1) :2580104.
  • CAS Number :

    [1789738-04-0]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide